Top

Pathology & Oncology Research

Published in:

01-01-2016 | Letter to the Editor

The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis

Authors: Matthew Goodyer, Stephen E. Langabeer, Karl Haslam, Karen Murphy

Published in: Pathology & Oncology Research | Issue 1/2016

Excerpt

To the Editor: …

Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730–747CrossRefPubMed

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissue, 4th ed. International Agency for Research on Cancer, Lyon

Langabeer SE, Andrikovics H, Asp J, et al (2015) Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 95:270–279

Dentali F, Squizzato A, Brivio L, et al (2009) JAK2 V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113:5617–5623CrossRefPubMed

Pardanani A, Lasho T, Schwager S, et al (2007) JAK2 V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 21:1828–1829CrossRefPubMed

Toyama K, Karasawa M, Yamane A, et al (2009) Low allele burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome. Int J Hematol 89:517–522CrossRefPubMed

Colaizzo D, Amitrano L, Guardascione MA, et al (2013) Outcome for patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99–e104CrossRefPubMed

Haslam K, Molloy KM, Conneally E, Langabeer S (2014) Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Clin Chem Lab Med 52:e29–e31CrossRefPubMed

Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS (2014) JAK2 V617F somatic mutation in the general population: myeloproliferative neoplasms development and progression rate. Haematologica 99:1448–1455PubMedCentralCrossRefPubMed

10.

Lippert E, Mansier O, Migeon M, et al (2014) Clinical and biological characterization of patients with low (0.1–2 %) JAK2 V617F allele burden at diagnosis. Haematologica 99:e98–e101CrossRefPubMed

Title: The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis
Authors: Matthew Goodyer
Stephen E. Langabeer
Karl Haslam
Karen Murphy
Publication date: 01-01-2016
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-015-9994-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

The Establishment and Utility of a Free Online Database of Primary Bone Tumors

The Assessment of the Magnitude of Frontal Plane Postural Changes in Breast Cancer Patients After Breast-Conserving Therapy or Mastectomy – Follow-up Results 1 Year After the Surgical Procedure

Expression of LC3, LAMP2, KEAP1 and NRF2 in Salivary Adenoid Cystic Carcinoma

Association Between Single Nucleotide Polymorphism +276G > T (rs1501299) in ADIPOQ and Endometrial Cancer

Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer